Aytu Biopharma Inc - AYTU STOCK NEWS

Aytu BioPharma (NASDAQ:AYTU) has announced it will report its financial results for the second quarter of fiscal year 2023, ending December 31, 2022, on February 14, 2023, after market close. A conference call will take place the same day at 4:30 pm ET to discuss the results. Interested participants can join by calling (888) 506-0062 or (973) 528-0011 with access code 371594. A live webcast will be available and archived for 90 days. Aytu specializes in pediatric-focused prescription drugs and consumer health solutions, including treatments for ADHD and various vitamin products for children.

Aytu BioPharma, Inc. (NASDAQ:AYTU) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The notification from Nasdaq confirms that Aytu's common stock closed at $1.00 per share or higher for ten consecutive business days, from January 6 to January 20, 2023. The issue is now resolved as per Listing Rule 5550(a)(2). Aytu specializes in pediatric-focused prescription drugs and consumer health products, and its portfolio includes medications for ADHD, allergy relief, and vitamin supplementation for children. This compliance is a positive development for Aytu's market position.

Englewood, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma (NASDAQ:AYTU) announces CEO Josh Disbrow will present at the Lytham Partners Investor Select Conference on January 31, 2023. The event will be held virtually, with a company webcast available at 9:00 am ET on the same day. The presentation can be accessed via the Aytu website. Additionally, management will hold one-on-one meetings with investors throughout the event. Interested parties can arrange meetings through Lytham Partners. Aytu specializes in pediatric-focused prescription drugs and consumer health solutions, including treatments for ADHD and various health products.

Aytu BioPharma is addressing the ongoing supply disruption of generic Adderall by promoting its FDA-approved bioequivalent, Adzenys XR-ODT. This medication is available as an orally disintegrating tablet, providing an alternative for ADHD patients unable to fill their Adderall prescriptions. Aytu's RxConnect program helps patients navigate insurance challenges, offering reduced out-of-pocket costs, often capped at $35 for commercially insured patients. The company emphasizes the importance of maintaining treatment continuity for individuals with ADHD during this time.

Aytu BioPharma (NASDAQ:AYTU) announced a 1-for-20 reverse stock split effective January 6, 2023, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. This decision follows approval from stockholders at a Special Meeting on October 5, 2022. Post-split, approximately 68.8 million shares will be reduced to about 3.4 million. A cash payment will be made for any fractional shares. The compliance deadline is May 22, 2023, requiring a consistent closing bid price of at least $1.00 for ten consecutive business days.

Aytu BioPharma announced a record 5,186 prescriptions for Adzenys XR-ODT for the week ending November 18, 2022, marking a 9.9% increase over the prior 13-week period. This increase is attributed to strong sales force execution and effective use of the Aytu RxConnect patient support program. Adzenys XR-ODT, an FDA-approved bioequivalent to Adderall XR, remains available without disruption, providing an alternative amid ongoing supply issues affecting Adderall. The company ensures consistent production at its Texas facility.

Aytu BioPharma has received a 180-day extension from Nasdaq to comply with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The deadline is set for May 22, 2023. Aytu must keep its stock price above $1.00 for at least 10 consecutive business days to regain compliance. The company is considering options, including a reverse stock split, to achieve this. If compliance is not met, Aytu’s stock could be delisted, although it can appeal any such decision. Aytu's stock continues to trade on Nasdaq under the symbol AYTU.

Aytu BioPharma has been ranked 94th on the Deloitte Technology Fast 500 and 21st among life sciences companies for the second consecutive year. This recognition highlights the company's growth, driven by a 47% increase in net revenue to $96.7 million in fiscal 2022, with an impressive 87% growth in prescription products sales. Aytu recently reported positive adjusted EBITDA in its first quarter of fiscal 2023. CEO Josh Disbrow emphasized the team's efforts in achieving commercial success and positive cash flows.

Aytu BioPharma (NASDAQ:AYTU) announced the passing of co-founder and board member Michael Macaluso on November 16, 2022. CEO Josh Disbrow expressed condolences, highlighting Macaluso's significant contributions since the company's inception in 2015. Macaluso served as Chair of the Compensation Committee and was integral to Aytu's growth, drawing on his four-decade entrepreneurial career in the life sciences sector. His diverse background included leadership roles at Ampio Pharmaceuticals and Isolagen, reflecting his deep industry expertise.